Vein-to-Vein | Kisaco Research
Strengthening the downstream processes of cell and gene therapies
Boston, USA
20-21 November, 2019
Download Agenda
The Audience
Register

Why Attend

The Vein-to-Vein Congress gathers manufacturing and supply chain heads from Biotechs, and pharmaceutical companies to address the industrialization and supply chain considerations that are being incorporated to facilitate commercial manufacture and delivery of cell therapies. The congress will discuss how to overcome the challenges including automation, storage, shipping and quality control. As the industry shifts from open and manual manufacturing to closed, automated and scalable systems the congress will discuss how to provide for greater product consistency, efficiency, and traceability throughout the process. With multiple steps and stakeholders in the process, the secret to a successful supply chain lies in mapping out the entire process and employing technology to mitigate risks. With case studies from across the oncology and autoimmune disease sectors, the Congress prepares you for a high production future.

Cell Therapy Event Gallery

CAR-T image gallery

TESTIMONIALS

CAR-T USA testimonials

WHO WILL BE THERE

Network with industry experts from:

  • Big pharma and biotech
  • Cell Therapy Academics and clinicians 
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers - CRO’s, Consultants, Government

Past attendees include:

CAR-T Usa Logo Cloud

The Agenda

The Vein-to-Vein Congress addresses the challenges of manufacturing cell therapies head-on. You’ll meet Heads of Manufacturing, CTOs, Heads of Supply Chain and Industrialization teams and learn how other teams are developing processes.

Take home actionable ideas and strategies from case studies delivered by the leading biotechs including Mustang Bio, Precision Biosciences and Immatics. In addition to learning about how they’re navigating the industrialization challenge, you’ll also meet with service partners that can help you take steps towards creating a seamless supply chain that meets quality and consistency requirements.

Take away answers to your primary manufacturing challenges including:

  • How Elevate Bio are overcoming limitations to economies of scale for manufacturing cell therapies by centralizing manufacturing to increase capital efficiency, improved product quality and more rapid time to market for cell and gene therapy products
  • How Mustang Bio are sourcing appropriate reagents, materials and equipment for cell therapy manufacturing at scale
  • How Immatics are implementing automation and standardizing methods for de-risking downstream processes
  • How Vita 34 are strengthening cell collection protocols to overcome variability in starting material and cell products
  • How Precision Biosciences are providing a blueprint for precise and efficient gene editing at scale

Download Agenda

The Speakers

 

Anthony Thatcher

US Head, Manufacturing Support and Technology
Cellectis

Anthony Thatcher

US Head, Manufacturing Support and Technology
Cellectis

Anthony Thatcher

US Head, Manufacturing Support and Technology
Cellectis
 

Knut Niss

Chief Technology Officer
Mustang Bio

Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr.

Knut Niss

Chief Technology Officer
Mustang Bio

Knut Niss

Chief Technology Officer
Mustang Bio

Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

 

 

Zoe Coughlin

Associate Director of CMC
Immatics

Zoe Coughlin is the Associate Director of CMC at Immatics US, Inc. in Houston, Tx leading the clinical manufacturing of adoptive cell therapy programs for various solid cancers. Zoe has more than 10 years of experience in GMP manufacturing of cell and gene therapy products and has helped guide all 4 Immatics’ active clinical trials through pre-clinical development, IND approval, and patient treatment. Before joining Immatics, Zoe was a Senior Clinical Cell Therapy Specialist at M.D.

Zoe Coughlin

Associate Director of CMC
Immatics

Zoe Coughlin

Associate Director of CMC
Immatics

Zoe Coughlin is the Associate Director of CMC at Immatics US, Inc. in Houston, Tx leading the clinical manufacturing of adoptive cell therapy programs for various solid cancers. Zoe has more than 10 years of experience in GMP manufacturing of cell and gene therapy products and has helped guide all 4 Immatics’ active clinical trials through pre-clinical development, IND approval, and patient treatment. Before joining Immatics, Zoe was a Senior Clinical Cell Therapy Specialist at M.D. Anderson Cancer Center involved in the manufacture and administration of multiple cell therapy products including the Sleeping Beauty transposon-based CAR-T program. Zoe holds a M.S. in Clinical Practice Management and maintains a MLS (ASCP)CM certification.

 

Mitchell h. Finer

Chief Scientific Officer/President
Elevate Bio/Elevate Bio, Base Camp

Mitchell h. Finer

Chief Scientific Officer/President
Elevate Bio/Elevate Bio, Base Camp

Mitchell h. Finer

Chief Scientific Officer/President
Elevate Bio/Elevate Bio, Base Camp
 

Wouter Van t'Hof

Cord Blood Bank Director
Cleveland Cord Blood Center

Wouter Van t'Hof

Cord Blood Bank Director
Cleveland Cord Blood Center

Wouter Van t'Hof

Cord Blood Bank Director
Cleveland Cord Blood Center
 

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr.

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr. Bhatia has lead multiple projects which include banking  of ESCs, iPSCs, MSCs and iPSC derived differentiated cells, development of GMP process for translational projects and manufacturing cell therapies for Phase I/II clinical trials. Dr. Bhatia has also lead efforts in quest for serum-free chemically defined culture medium for MSCs and development of platform technology for AAV production. Dr. Bhatia’s focus is on development of cGMP compliant manufacturing process for “bench to bedside” cell and gene therapies.

 

Steven Feldman

Director, Manufacturing and Development
Stanford Laboratory for Cell and Gene Medicine

Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years.  Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch.  Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.

Steven Feldman

Director, Manufacturing and Development
Stanford Laboratory for Cell and Gene Medicine

Steven Feldman

Director, Manufacturing and Development
Stanford Laboratory for Cell and Gene Medicine

Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years.  Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch.  Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.

 

Dr. Michael McGuire

CEO
Avectas

Dr. Maguire is President and CEO of Avectas, a cell engineering technology company. He has 20 years of experience in the life sciences industry, serving as a founder, investor, director and business leader. Dr. Maguire graduated from Trinity College, Dublin, as a biomedical engineer and completed his PhD on local drug delivery to the lung. Dr. Maguire is focused on creating value by addressing critical intracellular delivery challenges in cell therapies.

Dr. Michael McGuire

CEO
Avectas

Dr. Michael McGuire

CEO
Avectas

Dr. Maguire is President and CEO of Avectas, a cell engineering technology company. He has 20 years of experience in the life sciences industry, serving as a founder, investor, director and business leader. Dr. Maguire graduated from Trinity College, Dublin, as a biomedical engineer and completed his PhD on local drug delivery to the lung. Dr. Maguire is focused on creating value by addressing critical intracellular delivery challenges in cell therapies.

 

Kristina Carroll

Process Engineer, Process Development Group
Precision Biosciences

Kristina is a Process Engineer and founding member of the Cell Therapy Development team at Precision BioSciences, focused on the development of best-in-class manufacturing methods for allogeneic CAR T therapies.  As an integral part of the CMC team, Kristina led in the development of the large-scale manufacturing process, cold chain logistics for the cryopreserved drug product, and clinical administration protocols.  Prior to joining Precision BioSciences, Kristina worked as a Systems Engineer at Terumo BCT, focusing on upstream and downstream cell processing systems.  She has earned her Ma

Kristina Carroll

Process Engineer, Process Development Group
Precision Biosciences

Kristina Carroll

Process Engineer, Process Development Group
Precision Biosciences

Kristina is a Process Engineer and founding member of the Cell Therapy Development team at Precision BioSciences, focused on the development of best-in-class manufacturing methods for allogeneic CAR T therapies.  As an integral part of the CMC team, Kristina led in the development of the large-scale manufacturing process, cold chain logistics for the cryopreserved drug product, and clinical administration protocols.  Prior to joining Precision BioSciences, Kristina worked as a Systems Engineer at Terumo BCT, focusing on upstream and downstream cell processing systems.  She has earned her Master’s degree in Biomedical Engineering from Rutgers University and Bachelor’s degree in Chemical and Biological Engineering at the University of Colorado at Boulder. When not at Precision, Kristina can be found running nearby trails with her husband and dogs, camping, or creating a disaster in the kitchen.

 

Matthew Lehman

Board Director & CEO
Koligo Therapeutics

Matthew Lehman

Board Director & CEO
Koligo Therapeutics

Matthew Lehman

Board Director & CEO
Koligo Therapeutics
 

Angela Osborne

Managing Director
eXmoor Pharma Concepts

Angela Osborne

Managing Director
eXmoor Pharma Concepts

Angela Osborne

Managing Director
eXmoor Pharma Concepts
 

Dr. Wolfgang Knirsch

CEO
Vita34

Dr. Wolfgang Knirsch

CEO
Vita34

Dr. Wolfgang Knirsch

CEO
Vita34
 

Donna Rill

Chief Technology Officer
Triumvira Immunologics

Donna Rill

Chief Technology Officer
Triumvira Immunologics

Donna Rill

Chief Technology Officer
Triumvira Immunologics
 

John T. Elliott

Cell Systems Science Group Leader
National Institute of Standards and Technology

John T. Elliott

Cell Systems Science Group Leader
National Institute of Standards and Technology

John T. Elliott

Cell Systems Science Group Leader
National Institute of Standards and Technology
 

Colleen Murrett Sadin

Manager
Putnam Associates

Colleen Murrett Sadin

Manager
Putnam Associates

Colleen Murrett Sadin

Manager
Putnam Associates
 

Andrew Spiegal

Executive Director
Global Colon Cancer Association

Andrew Spiegal

Executive Director
Global Colon Cancer Association

Andrew Spiegal

Executive Director
Global Colon Cancer Association
 

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda
 

Derek Hei

Chief of Manufacturing & Technical Operations
BlueRock Therapeutics

Derek Hei

Chief of Manufacturing & Technical Operations
BlueRock Therapeutics

Derek Hei

Chief of Manufacturing & Technical Operations
BlueRock Therapeutics

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket prices increase in

Friday, October 11, 2019 to Saturday, November 23, 2019
Pharma & Biotech Standard Rate
$1,899
Standard Rate
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
Must have an active drug pipeline
To increase your brand presence, contact Nooran Dhillon, [email protected]
Friday, October 11, 2019 to Saturday, November 23, 2019
Vendors/Service Providers Standard Rate
$2,299
Standard rate
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Nooran Dhillon, [email protected]
Friday, October 11, 2019 to Friday, November 22, 2019
Clinician Standard
$1,099
Standard Rate
2 day conference pass
Must be a full-time healthcare professional
Networking opportunities
Refreshments, breakfast & lunch
To increase your brand presence, contact Nooran Dhillon, [email protected]
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Other events you might be interested in:

CAR-T Congress EU 2019

Therapeutic Genome Editing Congress

European Protein Degradation Congress